Precision Medicine Day One

 

Precision 2018 Day 1

08:00 Registration opens

08:50

Welcome from Terrapinn

Opening Keynotes: Implementing precision medicine into clinical practice

Nancy Krunic
09:00

Enabling real time oncology through the deployment of disruptive technologies

  • Apply the right biology
  • Leverage innovative technology
  • Analyse data rigorously
Joanne Hackett
09:25

Individualised medicine, and using the genome and digital technologies to understand disease and prevention

  • The value of genomics in healthcare
  • How Genomics England is catalysing the UK genomics landscape
  • How genomic data can diagnose and treat disease
  • Opportunities unique to the UK and why the time is now for harnessing the ecosystem

10:40 Networking Break

Diagnostics

Big Data and Genomics

Infrastructure and Investment

Diagnostics
11:40

Whole genome sequencing as a powerful clinical tool to treat cancers with an HPV etiology

  • Different types of whole genome sequencing- Illumina versus BGI
  • Importance of HPV integration to the eventual cancers that develop
  • Important clinical information gained from whole genome sequencing
  • How WGS information can drive the liquid biopsy
11:40

Integrative informatics at MedImmune, integrating data to answer scientific questions

  • MedImmune is building a semantically driven solution to scientific data integration
  • Driven by questions, we bring research and clinical data together in an exploratory context
  • We are using the FAIR principles (Findable, Accessible, Interoperable, Reusable)
11:40

Advancing innovation in personalised medicine through public private partnerships: The innovative medicines Initiative

  • Technology in the post human genome world is driving new disease taxonomies of disease and therefore new pathways for intervention
  • For some complex diseases like Alzheimer’s Disease, Type 2 Diabetes or Cancer, early stage developments can be achieved with lower risk and lower costs through PPPs
  • Patient engagement at early stages of R&D is critical for overall success
  • Bringing all stakeholders to the table including health economists, regulators, payers as well as Academics, Clinicians, SMEs, Patients and industry players is crucial for dealing with complex disease
Diagnostics
12:00

Advantages of large scale sequencing beyond conventional methods

  • Overview of methods for the integrated interpretation of somatic and germline data obtained from large-scale sequencing
  • Results obtained from these methods will be discussed
  • Advantages of large-scale data interpretation compared to conventional methods in cancer will be elucidated
12:00

Enablers for scaling up access to big health data

  • The challenges with accessing and combining health data sets at scale
  • Establishing trustworthy governance and privacy protection solutions
  • Data discovery and best practices in data sharing
  • Promoting the adoption of interoperability standards and data quality improvement
  • Demonstrating value to society from reusing their health data for research
12:00

Funding the future through impact investing

While many investors are primarily concerned with returns on investment, many investors and organizations are more dedicated to social returns through the application of capital. In this interactive session, we will discuss various funding sources such as:
  • Traditional venture capital
  • Family Offices and High Net Worth Individuals
  • Government sponsored programs
  • Foundations and Nonprofits
Diagnostics
12:20

cMyC - how a novel biomarker could transform chest pain triage

  • Cardiac Myosin-binding Protein C (cMyC) is a novel biomarker of myocardial injury.  Over the past 20 years, cardiac Troponin has transformed emergency care around the world
  • Our research demonstrates that cMyC is more abundant than the Troponins and at least as good as the leading Troponin assays in directing immediate triage of patients presenting with suspected acute non-ST elevation myocardial infarction.
  • This property, combined with the analytic sensitivity of our assay, suggests we can detect myocardial injury on a point-of-care platform; thus, improving cardiovascular care for millions of people
Diagnostics
12:20

Will computers be the better doctors soon? Real-world insights from oncology

  • How oncologists already benefit from interdisciplinary cooperation beyond doctors
  • When time matters: flexible real-time data analysis of big medical data at your fingertips using the AnalyzeGenomes.com platform
  • Application examples:
  • Accessing latest international medical expertise through the medical knowledge cockpit to enable personalized therapy decisions
  • Introducing next-generation sequencing to the clinical routine through reproducible high-throughput data processing
  • Individual assessment of available drugs through interactive drug response analysis
  • Enabling patients to manage their personal health data in a holistic way and support medical research at the same time through the data donation pass
Diagnostics
12:40

Chemical sensing microchip technology for liquid biopsies in breast cancer

  • Latest advances in chemical sensing microchip technology currently being used for genomics and point-of-care diagnostics
  • Recent and exciting results of our research towards the development of a sample-to-result, scalable, Lab-on-Chip system for early detection of breast cancer recurrence
12:40

Extended Q&A

13:00 Networking Lunch

Diagnostics

Investment Panel

Diagnostics
15:10

Extended Q&A

15:50 Networking break

Big Data

Jennifer Cham

Chaired by Jennifer Cham, Lead User Experience Architect, EMBL-EBI

Jennifer Cham
16:40

Advancing drug discovery and gaining a competitive advantage through user experience (UX)

  • Hear about the internal UX design capabilities of nine global research-based biopharmaceutical companies from a new investigation carried out in 2017
  • Find out how your organisation can benefit from a free UX toolkit for life science R&D designed by the Pistoia Alliance “User Experience for Life Sciences” (UXLS) initiative, a feat which involved over 50 UX design experts from 20 life science and tech organisations
  • Discover how UX offers a clear path to differentiating your business and reaping benefits for the discovery pipeline through specific case studies of UX in R&D
Maria Chatzou
17:00

How combining AI and genomics can advance treatment and diagnostics

  • How advances in AI and genomics are shaping medicine
  • The advantages of semantic integration of longitudinal omics data for improving diagnosis prediction
  • How AI-driven solutions can predict response to cancer treatment based on metagenomics information
  • How using AI methods improves traditional variant calling and mutation identification

Collaborations across precision medicine

Hakim Yadi
17:20

Collaboration at scale: Pan-regional precision medicines across the North of England's 15m population

  • The Northern Health Science Alliance
  • An overview of the North of England’s health research environment
  • Precision medicine industry engagement at scale
  • Pioneering precision medicine initiatives ready for scale up
Dr Mark Watson
17:40

Collaboration in MedTech translation: academia, industry and the regulator

  • CÚRAM is an Irish national medical device research centre with industry partners 
  • CRDI is partnering with CÚRAM in developing resources to navigate the regulatory environment 
  • This is well-aligned with the work of colleagues in developing methods of clinical and economic evaluation 

18:00 End of Day 1 - Networking drinks reception

last published: 15/May/18 12:55 GMT

 

DOWNLOAD BROCHURE

 

Sign Up for Event Updates

World Precision Medicine Congress

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Joan Shutt
t/ +44 (0)207 092 1134
joan.shutt@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com